 (Bos, 1988 
Summary In order to identify drugs active against mutated ras oncogenes we have developed an in vitro assay employing two clones of the human fibrosarcoma cell-line, HT1080 which carries an N-ras gene mutated at codon 61. Clone, HT1080scc2, retains the transformed phenotype of the parental line, whilst the other, HT1081c, is a morphologically flat, non-tumourigenic, revertant with under-representation of the chromosome carrying the transforming N-ras allele. The clear implication of mutant ras in maintaining the transformed nature of HT1080scc2 was confirmed when these cells were microinjected with the pan ras neutralising antibody Y13-259, which resulted in the morphological detransformation of these cells to a phenotype resembling that of the HT10801c clone. A number of known anti-cancer drugs with modes of action unrelated to ras function were found to be equipotent against both clones. However, when compounds chosen on the grounds of their potential selective cytotoxic or differentiating activity were tested some interesting results were obtained. Thus 8-bromo cAMP affected some morphological detransformation of HT1080scc2 cells and reduced their colony forming potential. The IMP-dehydrogenase inhibitors, tiazafurin and mycophenolic acid also flattened the morphology of the transformed clone. Fumagillin, an antibiotic reported to exhibit selective activity against ras transformed cells showed very marked and selective cytostatic effects against HT1080scc2 cells with IC50 values as low as 1 x 10-"M.
Mutated ras genes are associated with a wide variety of human tumours (Bos, 1988) . Chemical Tumour cells that would appear to suit this purpose are the transformed sub-line, HT1080-scc2 and the revertant subline, HT108001c both derived (Paterson et al., 1987) from the human fibrosarcoma cell line, HT1080 (Rasheed et al., 1974) . It has been established (Hall et al., 1983; Brown et al., 1984) that the parental HT1080 line contains an N-ras gene mutated (Gln-lys) at codon 61 and by Paterson et al. (1987) Assays for drug activity Assays for cell proliferation/cytotoxicity were carried out in tissue culture grade 96-well microtitre plates (Costar Ltd.) Cells in log growth were added to the plates at a concentration of 1 x IO0 cells per well on day 0 and serially diluted drugs were then added on day 1. Plates were then incubated at 37°C in 5% CO2 in air for a further 4 days.
For quantitation of cell growth, the methylene blue biomass staining method of Finlay et al. (1984) was used, the test being read on a Multiscan plate reader at a wavelength of 620 nm. The morphology of the cells was checked microscopically under phase-contrast immediately before fixation and staining with methylene blue, and by ordinary light microscopy thereafter. IC50 values for active compounds were obtained using the computer programme, GS1 and doseresponse slopes were also plotted.
Where compounds were tested for activity in a colony forming assay the methods used were identical to those described earlier except that serially diluted drug was added to the sloppy agar when the test was set up, and replenished at the same concentration on day 7. The results were read on day 14.
Results
Comparative growth and morphology of HT1080scc2 and HT10801c Growth rates in terms of cell number were similar for both lines to day 4 but thereafter HT1080scc2 cells continued to divide to reach saturation densities approximately 2 to 3 times higher than HT10801c by day 5 (Figure 1 ). Phenotypic differences between the two lines were clearly evident. HT10801c cells displayed a much flatter morphology then the transformed cells and only few mitotic cells were seen in confluent areas of the cultures. HT1080scc2 cells however continued to divide with numerous mitotic cells visible after confluence (Figure 2) .
Grown under anchorage independent conditions in soft agar, HT1080scc2 produced several large colonies whereas HT10801c cells failed to produce any colonies greater than 0.1 mm in diameter (Figure 3 Effects of known anti-cancer drugs on growth and morphology IC50 values for inhibition of growth obtained for each drug against both cell lines are given in Table I . All compounds were active against both lines with IC50 values ranging between less than 1 x 10-9 M (vincristine) to 1 x 10-5 M (melphalan). Individual compounds gave similar IC50 values phenotypic differences between their transformed and their immortalised or primary states and such differences should be quantifiable. Preferably, the cell lines used should also be of human origin. Growth characteristics and morphology of HT1080scc2 were consistent with the malignant phenotype in that the cells continued to divide after confluence, grew into multiple layers on plastic and also formed colonies in soft agar. HT10801c in very obvious contrast displayed contact inhibition in culture, a much flatter morphology with few mitotic cells seen after confluence and on inability to colonies under anchorage independent conditions. Such clear differences between sublines were similar to those reported previously by Paterson et al., 1987 and were sufficiently consistent to lend these lines for use in drug assays based on comparative morphology and cytotoxicity. Further, the microinjection experiments described in the present work demonstrated clearly that the malignant phenotype of the HT1080scc2 cells was dependent on ras expression and could be modulated to the detransformed phenotype on neutralisation of the oncoprotein by the ras-specific Y13-259 antibody. The susceptibility of both lines to known anti-cancer drugs was remarkably similar and probably reflects their common lineage. Such findings we consider important since it is well established that human tumour cell lines of analagous but not of homologous origin often differ greatly from one another with regard to their response to known anti-cancer drugs. It would indeed be potentially misleading and confusing to use cells with such widely different drug-responses as the test and control lines for identifying specific anti-ras drugs. No selective toxicity was seen against either line and none of the drugs induced any discernible detransforming effects on the HT1080scc2 cells. This itself was not surprising since these drugs are neither thought to modulate ras oncogenes nor to induce differentiation by any other mechanism.
Differential expression of type I and type II protein kinase isoenzymes has been shown to affect cell growth and differentiation (Gharret et al., 1976; Russell, 1978; ChoChung, 1980) and certain analogues of c-AMP including 8-bromo cAMP have been shown to modulate this differential expression in a spectrum of cancer cell lines (Katsaros et al., 1987; Ally et al., 1989) . The latter authors also showed that treatment with the compound decreased both N-ras and c-myc mRNA levels in lung tumours. Such observations are compatable with the present results where 8-bromo cAMP had a distinct and discernible detransforming effect on the HT1080scc2 cells consistent with the restoration of normal gene regulation in a ras oncogene driven tumour cell-line in which cAMP receptor proteins play a role in proliferation.
Inhibitors of IMP-dehydrogenase deplete guanylate levels within cells thereby eliciting a wide variety of intracellular effects including the down-regulation of ras oncogene expression (Olah et al., 1988) . The two IMP-dehydrodgenase inhibitors, mycophenolic acid and tiazafurin both flattened the morphology of HT1080scc2 cells and it is speculated that these effects may have been the result of ras downregulation. Neither compound however was effective at non-cytotoxic concentrations.
The post-translational farnesylation of ras proteins is an essential prequisite for their translocation to cell membranes (Casey et al., 1989) and the inhibition of this process through the inhibition of HMG-CoA reductase, a key rate-limiting enzyme in the mevalonate pathway, should result in the depletion of membrane-associated p21. In our hands, one such inhibitor, mevinolin, was toxic to both the transformed and the revertant lines with no discernible detransforming effects on HT1080scc2. Clearly inhibition of HMG-CoA reductase could well be toxic to cells since the enzyme lies far upstream to the protein farnesylation step. The extreme activity of fumagillin against HT1080scc2 cells deserves further investigation. This compound has antitumour activity which has been associated with its antiangiogenic activity (Ingber et al., 1990) and it also has been claimed (Merrimen et al., 1990) to be selectively cytotoxic in a clonogenic assay against mouse mammary epithelial cells transformed by K-and H-ras oncogenes. The potency of the compound however was not as great as that displayed against HT1080scc2 and, at least in our assays, the compound appeared to be cytostatic rather than toxic, at a very broad range of concentrations. Clearly the cytostatic effects seen by us cannot in any way be directly associated with the compound's known anti-angiogenic activity, and at present we have no proof that the compound modulates ras oncogene function.
More information is required, with regard to the response of these two HT1080 sublines to a wider range of experimental compounds, before valid conclusions can be drawn as to their usefulness for evaluating compounds for anti-ras activity. We recognise that unlike HT1080, the majority of ras-associated human tumours of clinical importance are adenocarcinomas of epithelial origin and that they usually express K-rather than N-ras oncoproteins. Further, they usually carry mutations at codon 12 or 13 rather than at 61 (Yanez et al., 1987) . The significance of these differences is not known. A marked degree of homology exists between K-, N-and H-ras gene products (Barbacid, 1987) and we consider that compounds designed to bind to their nucleotide binding domains and modulate their function, are unlikely to prove specific for any particular ras sub-type. However, it is possible that compounds which interfere with the posttranslational modification of ras proteins might show selectivity for one ras sub-type relative to another. Such, for example, could be anticipated if a compound interfered with the palmitoylation of p21. H-and N-ras proteins require palmitoylation prior to their translocation to the cell membrane (willumsen et al., 1984; Buss & Sefton, 1986 ) but K-ras protein on the other hand does not (Hancock et al., 1989) . Despite such possible shortcomings, the HT1080scc2 and HT10801c clones offer an unique opportunity for the screening of compounds for anti-ras activity against a human tumour cell line where the test clone's malignancy has been shown to be dependent on the expression of mutant ras protein, and the non-tumourigenic control clone with its markedly different phenotype is of the same lineage.
